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Abstract To document the rate of self-reported
compliance and glaucoma-related knowledge in Swiss
patients and to identify risk factors for their poor
compliance. This was an observational study, includ-
ing a total of 200 consecutive patients already under
glaucoma medication in two Swiss tertiary glaucoma
clinics (Geneva and Bern). Personal characteristics,
presence of systemic disease, compliance with glau-
coma medication, attitude to the ophthalmologist, and
glaucoma-related attitudes were ascertained by means
of a predetermined questionnaire with 40 questions.
Patients were subsequently assessed for the ability to
correctly instil placebo eye drops. Non-compliance
with glaucoma medication was defined as omitting
more than two doses a week as reported by the patient.
Logistic regression was used to evaluate how patient
characteristics and knowledge about the disease were
related to compliance. Overall, 81% (n = 162) of
patients reported to be compliant. Forgetfulness was
the most frequently cited reason for non-compliance
with dosing regimen (63%). Although 90.5%
(n = 181) of patients believed glaucoma medication
to be efficient, only 28% (n = 56) could correctly
define glaucoma. Factors positively associated with
compliance were ‘knowledge of glaucoma’ [adjusted
odds ratio (OR) 4.77 (95% CI 1.36–16.70)] and
‘getting help for administration of drops’ [OR 2.95
(1.25–6.94)]. These findings indicate that despite the
comparatively high compliance rate among glaucoma
patients, knowledge of glaucoma remains poor in
long-term glaucoma sufferers. Improving knowledge
about the disease is important since it is positively
associated with compliance in our study.
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Introduction
Compliance with a medication regimen is generally
defined as the extent to which patients take medication
as prescribed by their physician. It is established that
compliance with a prescribed drug regimen is often
inadequate particularly among patients on long-term
medication for chronic disease, including ophthalmic
diseases [1–3]. Among these, glaucoma patients
constitute the most important group as it is the second
leading cause of blindness worldwide [4]. At present,
the only treatable risk factor for glaucoma progression
is elevated intraocular pressure (IOP). The fact,
however, that glaucoma treatment is considered
palliative rather than curative as well as the general
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absence of symptoms in glaucoma patients increases
their risk of non-compliance. Analysis of the Collab-
orative Initial Glaucoma Treatment Study identified
an important role of compliance for IOP control during
treatment [5]. In the light of these findings, high rates
of non-compliance with glaucoma treatment in differ-
ent populations constitute a significant public health
concern.
There is no standardised methodology for mea-
surement of compliance, and there is generally a lack
of agreement in compliance findings between mea-
surement methodologies [6]. Progression of glaucoma
despite medical therapy is generally dealt with by
adding more potent compounds or resorting to
surgery. This could potentially be inappropriate as
patient’s non-compliance with the prescribed regimen
rather than drug inefficacy may be the underlying
factor. Therefore, specific information on the risk
factors for non-compliance is important in formulating
practical policies for glaucoma care. We report here
the findings of a study to ascertain the extent of
patients’ non-compliance and knowledge about their
disease in a Swiss hospital setting and their contrib-
uting risk factors.
Materials and methods
This was a cross-sectional, observational cohort study.
We enrolled 200 consecutive patients receiving ocular
hypotensive treatment for primary open-angle glau-
coma (POAG) in two linguistically distinct Swiss
tertiary glaucoma clinics (University Department of
Ophthalmology Geneva, glaucoma sector, henceforth
referred to as ‘centre 1’, and University Department of
Ophthalmology Bern, glaucoma sector, ‘centre 2’).
Each centre recruited 100 patients. The participants
were diagnosed in the past with POAG and had been
taking one or more hypotensive drugs for at least 6
months. The diagnosis of POAG required typical
glaucomatous optic nerve damage and visual field
abnormalities with or without a history of high IOPs.
Institutional Review Board approval was obtained and
all patients signed an informed consent. We developed
a structured questionnaire based upon the existing
literature. A pilot study on 10 patients was performed
and their suggestions were used to develop a final
version. The questionnaire consisted of 40 questions.
The first part dealt with the practice of glaucoma
treatment and knowledge about glaucoma. The second
part included general personal characteristics. On
average, it took patients 15 min to complete the
questionnaire.
After enrolment in the study and signing an
informed consent, patients were handed the question-
naire and were given sufficient time to complete it
before leaving the clinic. All patients were informed
that the questionnaire would remain anonymous and
no negative consequence for the follow-up would arise
from their participation and responses. In accordance
with the published literature, clinically significant
non-compliance was defined as omitting more than
two doses of glaucoma medication during any given
week [7]. Knowledge of glaucoma was defined as
being able to give a simple, correct explanation of the
disease. The acceptability of the answers was assessed
by two investigators whose agreement was required.
In case of disagreement, a third investigator adjudi-
cated. To evaluate unintentional non-compliance
(dyscompliance), patients were asked to demonstrate
the instillation of placebo eye drops. A drug bottle
containing sodium chloride 5.0% was used for this
purpose. Patients were categorised as ‘successful’ if
they were able to instil the drop correctly, kept the eye
closed afterwards for a minimum of 1 min and/or
exercised pressure on the punctum for at least 1 min,
‘moderately successful’ if they had to try more than
once to instil their drop, and ‘unsuccessful’ if they
touched the eye or missed the eye more than 50% of
the time. Patients who did not apply their own drops
were asked to describe exactly how the drop instilla-
tion was performed at home.
Statistical analysis
Sample size calculation was based on a 25% compli-
ance rate as the reference value. For each centre to
reach a power of 1 - b = 0.90, given a = 0.05 with
an acceptable error of 10%, 70 patients were needed.
We increased this sample to 100 to account for
incomplete answering. Descriptive statistics were
calculated for 19 independent variables (e.g., number
of drops, duration of glaucoma treatment, family
history of glaucoma, age, gender, systemic disease,
family status, and education) and for dependent
variables (compliance and glaucoma knowledge).
Next, bivariate analysis was used to examine vari-
ables associated with compliance and knowledge.
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Associations with a P value of\0.2 or those that could
logically or intuitively be considered to be related to
patient compliance or knowledge were retained for
further analysis. Multiple logistic regression analysis
was then used to examine how the preselected
variables were associated with compliance and knowl-
edge. We also tested the effect of centre as a
categorical variable. The model was then refined by
using a standard stepwise backward elimination
procedure. After each regression run, we eliminated
the independent variable showing the least significant
relationship to the outcome of interest. The process
was continued until only variables with P values\0.05
were left. Statistical analysis was performed with the
Stata 9.0 software package.
Results
Two hundred patients were included from the two
centres (100 each). We obtained 160 complete and 40
incomplete records. All records were included in the
analysis. In all, 52.5% of patients were on a single
topical glaucoma medication, 36% on two medications,
11% on three medications, and 0.5% on four medica-
tions. Table 1 presents the complete demographic
characteristics of the patients. Table 2 provides an
overview of the type of medication used by participants.
Glaucoma had been discovered during a routine
ophthalmic examination by their ophthalmologist in
93 patients (46.5%), at a tertiary referral centre
(n = 49, 24.5%), based on suspicion by an optician
(n = 9, 4.5%), general practitioner (n = 6, 3.0%), due
to personal awareness secondary to media coverage
(n = 7, 3.5%) or affected family members (n = 5,
2.5%). Duration of glaucoma was less than a year in 25
patients (12.5%), between 1 and 3 years in 51 (25.5%),
between 4 and 5 years in 36 (18.0%), between 6 and
10 years in 34 (17.0%), and[10 years in 42 patients
(21.0%). The rest of the patients could not give an
answer. Fifty-nine (29.5%) patients reported a positive
family history of glaucoma.
Table 1 Patient
demographics (n = 200)
NS statistically not
significant, CHF Swiss
Franc
Geneva Bern Both centres P
(n = 100) (n = 100) (n = 200)
Age (mean, SD) 64.4 (±14.1) 68.3 (±12.9) 66.3 (±13.6) 0.05
Gender
Male 41% (41) 49% (49) 45.5% (91) NS
Female 59% (59) 51% (51) 54.5% (109) NS
Income
\5000 CHF 21% (21) 33% (33) 27.0% (54) NS
5001–8000 CHF 10% (10) 13% (13) 11.5% (23) NS
[8000 CHF 14% (14) 6% (6) 5.0% (20) \0.05
No answer 55% (55) 48% (48) 51.5% (103) NS
Education
Primary 60% (60) 79% (79) 69.5% (139) \0.05
Secondary 10% (10) 9% (9) 9.5% (19) NS
Tertiary 14% (14) 7% (7) 10.5% (21) \0.05
Social status
Married 45% (45) 58% (58) 51.5% (103) NS
Divorced 12% (12) 12% (12) 12.0% (24) NS
Widower 20% (20) 22% (22) 21.0% (42) NS
Bachelor 20% (20) 7% (7) 13.5% (27) \0.05
No. of glaucoma medications
1 62% (62) 43% (43) 52.5% (105) \0.05
2 33% (33) 39% (39) 36.0% (72) NS
3 5% (5) 17% (17) 11.0% (22) \0.05
4 0 1% (1) 0.5% (1) NS
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Inability to administer eye drops correctly (termed
as dyscompliance) was found in 7%, acceptable
method of instillation in 28% and good mode of
instillation in 64%. Presence of self-reported arthritis
(RR 2.05; 95% CI 1.30–2.88) was significantly
associated with dyscompliance. Age over 60 years
(RR 1.76; 95% CI 1.07–1.91) and lower educational
level (RR 1.16; 95% CI 1.02–1.33) were significantly
associated with the practice of waiting less than 3 min
between different glaucoma drops.
One hundred and thirteen patients (56.5%) stated
that they never forgot a single drop, 36 (18.0%) that
they forgot one drop a week, 13 (6.5%) that they forgot
two drops a week, and nine patients (4.5%) forgot
more than two drops in a week. The remainder could
not give an answer. Therefore, according to our
definition, the rate of compliance was 81.0%
(n = 162; 95% CI 75.6–86.4). Compliance was sig-
nificantly higher in patients from Bern compared to
those from Geneva (87 vs. 75%, P = 0.031). This
difference was chiefly due to a higher number of
participants who did not give an answer at centre 1 and
were therefore categorised as non-compliant. The
main reasons for defaulting were (in descending
order): forgetfulness (63%), being away from home/
travel (16%), inconvenience during work (7%), diffi-
culty to instil the drops (4%), eye irritation (3.5%),
disbelief in efficiency of drops (3.5%), and other
reasons (3%).
The most frequent method to remember therapy
was daily application at the same time (n = 150,
75.0%), followed by reminding through family mem-
bers or partners (n = 8, 4.0%), and use of an alarm-
clock/device (n = 6, 3.0%). No side-effects of
medical glaucoma therapy were felt by 60.5% of
patients, while 14% experienced moderate to severe
side-effects, the most frequent being severe burning of
the eye (5.0%). We did not find any effect of age on the
reporting of side-effects. Of those patients who
suffered from side-effects, only 5% had stopped the
treatment before consulting their physician. No rela-
tionship between reporting of side-effects and com-
pliance was found. Ninety percent of respondents felt
their glaucoma treatment to be useful, out of which
53% believed it to be very useful, while the rest
believed it had little or no effect at all. Sixty-eight
percent claimed to always study the package infor-
mation of new glaucoma medication. A total of 79.6%
administered their own drops, while 4.8% required
occasional assistance, and 14.2% required frequent
assistance. Concerning the goal of therapy, 136
patients (68.0%) believed it to be maintaining current
vision, 32 (16.0%) believed it to be improving vision
and 7 patients (3.5%) believed in other reasons.
Knowledge about glaucoma (Odds ratio (OR) 4.77;
95% CI 1.36–16.70), and assistance by others to
administer the glaucoma drops (OR 2.94; 95% CI
1.25–6.94) were positively associated while recruit-
ment at Geneva was negatively associated (OR 0.35;
95% CI 0.15–0.80) with compliance in a multiple
regression model. No association could be found
between compliance with the glaucoma treatment and
the total number of glaucoma drops (OR 0.91; 95% CI
0.33–2.50), positive family history of glaucoma (OR
4.32; 95% CI 0.85–21.89), gender (crude OR 0.74;
95% CI 0.40–1.35), tobacco smoking (OR 0.21; 95%
CI 0.02–2.21), use of optical correction (OR 0.51;
95% CI 0.16–1.61), or previous eye surgery (crude OR
1.05; 95% CI 0.58–1.96). Table 3 shows a complete
list of compliance-related factors as crude OR and
after multiple logistic regression analysis.
Knowledge about glaucoma
Patients were asked to describe the term ‘glaucoma’ in
simple words. Only 56 (28%) could give a correct
answer, 43 (21.5%) gave an incorrect or insufficient
description, and the remaining 50.5% gave no answer
at all. Ninety (45.0%) patients knew the value of their
highest measured IOP and 74 (37%) also knew their
highest IOP before the start of medical therapy. On
multivariate analysis, level of education was posi-
tively associated with knowledge about glaucoma (OR
Table 2 Type of medication used in the Swiss Compliance
Trial (including multiple therapy)
Medication Patients,
no. (%)
Prostaglandin analogue 104 (52)
Carbonic anhydrase inhibitors/b-adrenergic
antagonist combination
50 (25)
b-Adrenergic antagonist 32 (16)
a-Agonist 31 (15.5)
Carbonic anhydrase inhibitors 28 (14)
Prostaglandin analogue/b-adrenergic antagonist
combination
15 (7.5)
a-Agonist/b-adrenergic antagonist combination 11 (5.5)
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2.00; 95% CI 0.98–4.09, P \ 0.05), while the lack of
interest for additional glaucoma information was
negatively associated with knowledge (OR 0.26;
95% CI 0.11–0.59, P \ 0.01) (Table 4). Only 43.5%
of participants reported their income level and there-
fore this variable was excluded from the model. All
other factors did not show any significant association
with better knowledge. Seventeen patients (8.5%)
were not sure whether they suffered from glaucoma
and two patients (1%) thought that they did not.
Discussion
This is the first study investigating the rate of
compliance and glaucoma-related knowledge in Swiss
patients. With 81% reporting to omit no more than two
glaucoma doses per week, self-reported compliance in
this Swiss cohort was substantially higher than that
reported in other studies [6–11]. Using the same
definition, Konstas et al. [12] distributed question-
naires to 100 Greek patients and showed 29% non-
compliance, while 56% claimed to never miss a single
dose. This rate is almost identical to our cohort
(56.5%). Similarly, a Canadian multicentre study
reported an overall proportion of non-compliance of
27.9% [11]. Rigal et al. [13], using the questionnaire
developed for the present study, reported a 90%
compliance rate in 100 Austrian patients of a specia-
lised glaucoma practice. That study, however, was
carried out in a smaller setting which can explain the
exceptionally high compliance rate. Sleath et al. [8]
reported that the rate of non-compliance (defined as
less than 100% adherence in the previous week) was
14% in four different private practices. The clinical
relevance of such a definition, however, can be
Table 3 Patient-reported compliance and its examined predictors
Independent variables Crude OR Adjusted OR Last retained variables
Point
estimate
95% CI P value Point
estimate
95% CI P value Point
estimate
95% CI P value
Age above 60 years 1.04 0.54–2.00 0.91
Gender: female 0.74 0.40–1.35 0.31
Years of education 1.41 0.60–3.32 0.42
Work: active 2.60 0.96–7.07 0.04 1.35 0.34–5.24 0.66
No. of glaucoma
medications
0.99 0.56–1.76 0.98 0.91 0.33–2.50 0.86
Duration of glaucoma:
C5 years
1.20 0.65–2.22 0.56
Family history of
glaucoma: positive
1.57 0.77–3.22 0.20 4.32 0.85–21.89 0.07
Knowledge of glaucoma 4.54 1.45–14.16 0.002 3.03 0.59–15.32 0.17 4.77 1.36–16.70 0.01
No desire for
information
0.66 0.36–1.20 0.17 0.97 0.33–2.85 0.96
Living as a couple 0.79 0.43–1.44 0.44
Help with drop
administration
2.41 1.33–4.38 0.004 4.28 1.43–12.84 0.009 2.94 1.25–6.94 0.01
Use of optical correction 0.61 0.33–1.12 0.12 0.51 0.16–1.61 0.25
Previous eye surgery 1.04 0.58–1.96 0.84
Vascular dysregulation 0.99 0.48–2.05 0.98
Migraine 1.16 0.52–2.60 0.72
Diabetes 2.18 1.01–4.70 0.05 1.83 0.54–6.20 0.33
Arthritis 1.66 0.88–3.14 0.12 0.79 0.24–2.62 0.70
Smoking 0.37 0.09–1.47 0.12 0.21 0.02–2.21 0.19
Centre: Geneva 0.52 0.28–0.96 0.03 0.33 0.11–0.98 0.04 0.35 0.15–0.80 0.01
CI confidence interval
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contested as it is generally assumed that patient
compliance may increase shortly before the scheduled
medical appointment [14]. Higher rates of non-com-
pliance have been reported in a number of publications.
Spooner et al. [15] while addressing discontinuation
found non-compliance in 38% of glaucoma patients.
Khandekar et al. [7] used a different approach based on
questions related to compliance and calculated an
overall score in an Omani population. They showed
‘excellent’ overall compliance in 24.8% but some type
of non-compliance was noted in 75.2% of the respon-
dents. The wide variety in compliance rates reported in
the literature has several explanations, the main ones
being varying definitions of compliance and different
appraisal methods.
There is no consensual standard for what consti-
tutes clinically adequate compliance. Cut-off levels
for non-compliance have varied according to studies
from missing more than one dose per month to not
having taken any prescription over a period of 12
months. We applied the definition most used in recent
publications, which is up to two missed doses per
week. This limit is in itself imperfect since two missed
doses per week might not have the same clinical
implication depending on overall number of drops and
glaucoma severity. When we used a stricter definition
of compliance (less than two missed doses per week),
74.5% were still compliant with their medication. One
reason for the high compliance in our sample could be
the fact that financial considerations of medical
therapy do not play a major role since all our patients
were insured and got 90% of the treatment costs
reimbursed.
It has been reported that compliance would be
improved by a simpler drug regimen [16]. To our
surprise, no such correlation could be found in the
present cohort. This finding is in accordance with
Okeke et al. [17, 18] who showed that adherence with
once-daily prostaglandin was not substantially higher
than previously reported compliance rates with beta-
blockers twice-daily or pilocarpine 4 times daily. In
another study, 58 Hungarian patients treated with a
once-daily prostaglandin failed to show such an
association [19]. In contrast, Sleath et al. [8] found
that patients taking more glaucoma medications were
more likely to have poor compliance and more
problems taking their eye drops. At the current
state of knowledge, the evidence for improved
Table 4 Knowledge and its examined predictors
Independent variables Crude OR Adjusted OR Last retained variables
Point
estimate
95% CI P value Point
estimate
95% CI P value Point
estimate
95% CI P value
Age above 60 years 0.87 0.69–1.08 0.17 1.87 0.60–5.79 0.27
Gender: female 0.95 0.80–1.14 0.59 1.10 0.51–2.38 0.79
Years of education 1.29 1.00–1.65 0.02 1.45 0.63–3.35 0.37 2.00 0.98–4.09 0.05
Work: active 1.59 1.19–2.11 \0.01 3.85 1.36–10.90 0.01
Duration of glaucoma: C5
years
1.24 1.01–1.52 0.02 1.90 0.88–4.10 0.10
Family history of glaucoma:
positive
1.17 0.94–1.44 0.12 1.13 0.51–2.52 0.75
No desire for information 0.69 0.58–0.82 \0.01 0.25 0.10–0.64 \0.01 0.26 0.11–0.59 \0.01
Living as a couple 1.05 0.88–1.25 0.62
Use of optical correction 0.94 0.77–1.14 0.54
Previous eye surgery 1.03 0.86–1.24 0.72
Vascular dysregulation 0.85 0.68–1.06 0.12
Migraine 1.07 0.85–1.34 0.60
Diabetes 1.40 1.21–1.62 0.01 5.52 0.67–4.56 0.11
Smoking 0.88 0.66–1.18 0.35
Centre: Geneva 1.03 0.86–1.22 0.75
CI confidence interval
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compliance—the main advantage of combination
drugs—with fewer doses remains contested. Further-
more, we found that patients reporting side-effects had
equal compliance rates to those not reporting them.
This counterintuitive finding was also reported by
Friedman et al. [20] in a recent study on 196 patients
from two specialised glaucoma clinics monitored
using the Travatan Dosing Aid.
We found that 79.6% of patients always adminis-
tered their own drops while 14.2% often or always
relied on assistance. This rate is comparable to Sleath
et al. [8] who reported a 13% dependency rate. These
patients were likely to be older than 60 years, suffer
from arthritis and using multiple glaucoma therapy. In
multivariate regression analysis, getting help with
administration emerged as the second most important
predictor of good compliance.
With 28% correctly defining glaucoma, the level of
knowledge about glaucoma in our cohort was low. This
might have been influenced by asking the patient to
actively define glaucoma rather than offering him/her
the choice between multiple choice answers. A tele-
phone survey of normal households in Switzerland
showed similar findings with only 24.7% of intervie-
wees being able to describe glaucoma as an eye disease
[21]. We therefore believe that the true rate of knowl-
edge in our cohort may be higher but that a significant
number may not feel confident enough to expose their
knowledge in the chosen study format. Low levels of
knowledge should be a matter of concern. Most studies
have suggested that patient education can enhance
compliance in glaucoma patients based on observation
[6, 13, 17, 22]. Particularly worrying in our study was
the finding that positive family history (almost 30% of
patients) did not improve the level of knowledge in this
cohort (OR 1.13; 95% CI 0.51–2.52).
Limitations
The present study has several inherent limitations.
First, our study was conducted in two university-based
glaucoma clinics in two linguistically different Swiss
cantons. Therefore, it could be affected by selection
bias and not reflect glaucoma patients in the commu-
nity. The second limitation is that self-reporting has
inherent weaknesses, the main one being a tendency of
a patient to give favourable answers to please the
physician. Hollo et al. [23] measured the influence of
psychological characteristics on compliance with
glaucoma medication. They found that social desir-
ability was significantly increased in a cohort of
glaucoma patients as compared with normal subjects.
Not surprisingly, studies that use medication monitors
or completed prescription data as a surrogate for
patient compliance consistently show higher rates of
non-compliance [6, 11, 20]. High rates of compliance,
however, are not uniquely observed in questionnaire-
based studies. A mean coverage of 97% was found in
an electronic monitoring study [16]. Furthermore, de
Klerk et al. [24] have shown that questionnaires can
have a similarly good predictive value compared to the
electronic medication monitoring. In our questionnaire
we tried to normalise patients’ behaviour by asking in a
non-judgemental way that ‘‘Glaucoma is a chronic
disease and it is often difficult to put ones’ eye drops
regularly. Does it happen to you to omit a dose?’’ Later
in the questionnaire, we included a control question
(‘‘Do you always take your eye drops?’’). We found
almost perfect agreement (89%) between the answers
to both questions. We further tried to reduce this bias by
guaranteeing anonymity and having non-medical per-
sonnel act as intermediaries. Another limitation was
our method for assessing the level of knowledge, which
was based on subjective evaluation by the investiga-
tors. Two investigators had to agree whether the
provided definition of glaucoma was acceptable. This
might have introduced some inconsistencies; however,
the rationale behind this approach was to provide
flexibility instead of a creating arbitrary definition
criterion in the absence of a uniform case definition for
glaucoma. A strength of our study is that we asked
about other disease states that could impact a patient’s
ability to use his/her eye drops. We found a significant
association between dyscompliance and self-reported
arthritis (crude OR 1.62; 95% CI 1.03–2.69), which
goes hand-in-hand with the strong association between
getting help for drop administration and better com-
pliance (OR 2.94; 95% CI 1.25–6.94). Another
strength of the present paper is that contrary to most
studies that did not track those patients who declined to
participate in the survey, we had a high response rate
with only four patients refusing participation.
Conclusions
The present study provides new information about the
extent of glaucoma-related knowledge and risk factors
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for non-compliance. We were able to show that
despite high rates of compliance in Swiss patients
most seem to lack an adequate knowledge about their
disease. With knowledge of glaucoma being the
strongest predictor of adherence in our cohort,
ophthalmologists should put more emphasis on
information.
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